BAJAJ BROKING

Notification
No new Notification messages
Ather Energy IPO is Open!
Apply for the Ather Energy IPO through UPI in just minutes.
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.

2643

500680

PFIZER

img img img img
No Data Available

Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply

PFIZER LTD performance

Today’s low

Today’s high

₹ 4227.20 ₹ 4338.00
₹ 4292.80

52 week low

52 week high

₹ 3701.00 ₹ 6451.15
₹ 4292.80

Open Price

₹ 4250.00

Prev. Close

₹ 4268.40

Volume (Shares)

20540.00

Total traded value

₹ 881.74

Upper Circuit

₹ 5122.00

Lower Circuit

₹ 3414.80

info

PFIZER LTD Share Price Update

As of the latest trading session, PFIZER LTD share price is currently at ₹ 4292.8, which is up by ₹ 24.39 from its previous closing. Today, the stock has fluctuated between ₹ 4227.20 and ₹ 4338.00. Over the past year, PFIZER LTD has achieved a return of 0.83 %. In the last month alone, the return has been 6.36 %. Read More...

PFIZER LTD fundamentals


  • Market cap (Cr)

    19,638.60

  • P/E Ratio (TTM)

    31.94

  • Beta

    0.42

  • Book Value / share

    819.90

  • Return on equity

    16.21%

  • EPS (TTM)

    134.55

  • Dividend yield

    0.81%

  • Net profit/quarter (Cr)

    127.60

info icon alternate text
  • Market cap (Cr)

    19,661.70

  • P/E Ratio (TTM)

    31.94

  • Beta

    0.42

  • Book Value / share

    819.90

  • Return on equity

    16.21%

  • EPS (TTM)

    134.55

  • Dividend yield

    0.81%

  • Net profit/quarter (Cr)

    127.60

info icon alternate text

PFIZER LTD Financials

  • Key Results

  • Key Ratios

  • Balance sheet

  • Cash Flow

  • Competition

info-icon

Revenue

Net income

Particulars DEC 2024 (Values in Cr)
Revenue 537.99
Operating Expense 408.31
Net Profit 127.60
Net Profit Margin (%) 23.71
Earnings Per Share (EPS) 27.89
EBITDA 188.75
Effective Tax Rate (%) 26.00
Particulars SEP 2024 (Values in Cr)
Revenue 588.59
Operating Expense 416.43
Net Profit 158.35
Net Profit Margin (%) 26.90
Earnings Per Share (EPS) 34.61
EBITDA 232.32
Effective Tax Rate (%) 26.42
Particulars JUN 2024 (Values in Cr)
Revenue 562.86
Operating Expense 402.08
Net Profit 150.71
Net Profit Margin (%) 26.77
Earnings Per Share (EPS) 32.94
EBITDA 219.33
Effective Tax Rate (%) 25.61
Particulars MAR 2024 (Values in Cr)
Revenue 546.63
Operating Expense 377.90
Net Profit 178.86
Net Profit Margin (%) 32.72
Earnings Per Share (EPS) 39.09
EBITDA 264.56
Effective Tax Rate (%) 26.65
Particulars DEC 2023 (Values in Cr)
Revenue 539.97
Operating Expense 407.83
Net Profit 129.98
Net Profit Margin (%) 24.07
Earnings Per Share (EPS) 28.42
EBITDA 196.35
Effective Tax Rate (%) 26.12
Particulars MAR 2024 (Values in Cr)
Revenue 2193.17
Operating Expense 1635.56
Net Profit 551.33
Net Profit Margin (%) 25.13
Earnings Per Share (EPS) 120.51
EBITDA 823.76
Effective Tax Rate (%) 26.10
Particulars MAR 2023 (Values in Cr)
Revenue 2424.76
Operating Expense 1734.80
Net Profit 623.93
Net Profit Margin (%) 25.73
Earnings Per Share (EPS) 128.50
EBITDA 942.91
Effective Tax Rate (%) 24.28
Particulars MAR 2022 (Values in Cr)
Revenue 2610.99
Operating Expense 1900.75
Net Profit 612.56
Net Profit Margin (%) 23.46
Earnings Per Share (EPS) 133.89
EBITDA 898.38
Effective Tax Rate (%) 20.74
Particulars MAR 2021 (Values in Cr)
Revenue 2238.55
Operating Expense 1650.94
Net Profit 497.61
Net Profit Margin (%) 22.22
Earnings Per Share (EPS) 108.77
EBITDA 793.24
Effective Tax Rate (%) 25.58
Particulars MAR 2020 (Values in Cr)
Revenue 2151.65
Operating Expense 1693.17
Net Profit 509.13
Net Profit Margin (%) 23.66
Earnings Per Share (EPS) 111.28
EBITDA 756.58
Effective Tax Rate (%) 20.75
Particulars (Values in Cr)
Book Value / Share 301.97
ROE % 19.78
ROCE % 27.27
Total Debt to Total Equity 0.00
EBITDA Margin 28.89
Particulars (Values in Cr)
Book Value / Share 217.73
ROE % 27.44
ROCE % 37.35
Total Debt to Total Equity 0.00
EBITDA Margin 26.20
Particulars (Values in Cr)
Book Value / Share 135.97
ROE % 27.21
ROCE % 44.48
Total Debt to Total Equity 0.00
EBITDA Margin 22.81
Particulars (Values in Cr)
Book Value / Share 125.99
ROE % 23.74
ROCE % 42.64
Total Debt to Total Equity 0.02
EBITDA Margin 21.12
Particulars (Values in Cr)
Book Value / Share 117.53
ROE % 17.39
ROCE % 34.75
Total Debt to Total Equity 0.02
EBITDA Margin 15.05
Particulars MAR 2024 (Values in Cr)
Book Value / Share 785.91
ROE % 16.21
ROCE % 21.43
Total Debt to Total Equity 0.01
EBITDA Margin 37.56
Particulars MAR 2023 (Values in Cr)
Book Value / Share 701.05
ROE % 20.55
ROCE % 25.88
Total Debt to Total Equity 0.01
EBITDA Margin 38.89
Particulars MAR 2022 (Values in Cr)
Book Value / Share 626.10
ROE % 23.30
ROCE % 27.78
Total Debt to Total Equity 0.02
EBITDA Margin 34.42
Particulars MAR 2021 (Values in Cr)
Book Value / Share 523.07
ROE % 17.19
ROCE % 22.47
Total Debt to Total Equity 0.01
EBITDA Margin 35.45
Particulars MAR 2020 (Values in Cr)
Book Value / Share 742.18
ROE % 15.89
ROCE % 19.85
Total Debt to Total Equity 0.00
EBITDA Margin 35.17
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 2046.71
Total Assets 4228.78
Total Liabilities 4228.78
Total Equity 3595.54
Share Outstanding 45750372
Price to Book Ratio 5.34
Return on Assets (%) 13.03
Return on Capital (%) 15.32
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 1859.52
Total Assets 4000.73
Total Liabilities 4000.73
Total Equity 3207.30
Share Outstanding 45750372
Price to Book Ratio 4.94
Return on Assets (%) 15.59
Return on Capital (%) 19.44
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 1643.44
Total Assets 3900.51
Total Liabilities 3900.51
Total Equity 2864.41
Share Outstanding 45750372
Price to Book Ratio 6.95
Return on Assets (%) 15.70
Return on Capital (%) 21.37
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 1115.10
Total Assets 3265.90
Total Liabilities 3265.90
Total Equity 2393.04
Share Outstanding 45750372
Price to Book Ratio 8.64
Return on Assets (%) 15.23
Return on Capital (%) 20.77
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 2219.87
Total Assets 4405.40
Total Liabilities 4405.40
Total Equity 3395.49
Share Outstanding 45750372
Price to Book Ratio 5.42
Return on Assets (%) 11.55
Return on Capital (%) 14.98
Particulars MAR 2024 (Values in Cr)
Net Income 746.07
Cash from Operations 410.66
Cash from Investing 53.70
Cash from Financing -235.14
Net change in Cash 75.40
Free Cash Flow 429.59
Particulars MAR 2023 (Values in Cr)
Net Income 824.01
Cash from Operations 658.26
Cash from Investing -36.05
Cash from Financing -345.79
Net change in Cash -26.16
Free Cash Flow 723.24
Particulars MAR 2022 (Values in Cr)
Net Income 772.89
Cash from Operations 893.00
Cash from Investing -575.02
Cash from Financing -180.51
Net change in Cash -88.45
Free Cash Flow 908.31
Particulars MAR 2021 (Values in Cr)
Net Income 668.72
Cash from Operations 631.47
Cash from Investing -468.84
Cash from Financing -1571.07
Net change in Cash -1612.58
Free Cash Flow 649.17
Particulars MAR 2020 (Values in Cr)
Net Income 642.49
Cash from Operations 536.47
Cash from Investing 1530.32
Cash from Financing -163.52
Net change in Cash 1689.98
Free Cash Flow 553.36
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 36.46 19.60 1.99 279.41 34.11 / 77.70
BLISS GVS PHARMA LTD 119.00 15.60 1.24 1253.91 92.25 / 184.95
CIPLA LTD 1549.65 25.08 4.41 125155.99 1310.05 / 1702.00
FERMENTA BIOTECH LIMITED 260.70 21.60 2.64 767.27 145.00 / 449.00
GLAXOSMITHKLINE PHARMA LT 2959.45 58.70 29.97 50134.87 1924.30 / 3147.45
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 36.46 21.96 6.19 279.41 34.11 / 77.70
AMRUTAJAN HEALTH LTD 692.80 40.61 6.72 2002.93 548.05 / 861.40
ASTRAZENECA PHARMA IND LT 8665.50 129.24 31.88 21663.75 5000.00 / 9199.00
BLISS GVS PHARMA LTD 119.00 15.45 1.22 1253.91 92.25 / 184.95

PFIZER LTD Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
4292.80 0.57 redarrow
red-green-graph indicator
4 Bearish
12 Bullish
  • 5 Days 4267.50
  • 26 Days 4174.20
  • 10 Days 4233.10
  • 50 Days 4230.40
  • 12 Days 4220.00
  • 100 Days 4452.30
  • 20 Days 4184.00
  • 200 Days 4649.70
4259.07 PIVOT

First Support

4220.33

First Resistance

4307.13

Second Support

4172.27

Second Resistance

4345.87

Third Support

4133.53

Third Resistance

4393.93

RSI

62.62

ADX

14.40

MACD

45.81

Williams % R

-15.34

Commodity Channel Index (CCI)

95.30

Date

2025-04-30

Week

9862.00

Same Day

8636.00

Month

10447.00

1 Year

0.42

3 Year

0.37

Over 1 Month

6.36%

down

Over 1 Year

0.83%

down

Over 3 Months

-5.00%

down

Over 3 Years

-0.62%

down

Over 6 Months

-15.78%

down

Over 5 Years

-2.61%

down

Invest with Confidence

Left Arrow
MTF boost
Buy Now. Pay Later

Boost your capital upto 5 X

img
IPO boost
Invest in IPOs
They give good returns
img
Right Arrow

PFIZER LTD shareholding pattern

  • Shareholding Summary

  • Historical Promotor Holding

  • Historical MF Holding

  • Historical FII Holding

Holding

Others
16.79%
Promoter Holdings
63.92%
FII
2.18%
DII
17.1%
Promoter Shares(Pledge Percentage)
0.0%
Name Shares Category
Pfizer East India B V 1.8186334E7 (39.75%) Shareholding of Promoter and Promoter Group
Wyeth Llc 5617707.0 (12.28%) Shareholding of Promoter and Promoter Group
Nippon Life India Trustee Ltd 1906466.0 (4.17%) Public Shareholding
Life Insurance Corporation Of India 1797287.0 (3.93%) Public Shareholding
Wyeth Holdings Corporation 1630164.0 (3.56%) Shareholding of Promoter and Promoter Group
Warner-lambert Company Llc 1187163.0 (2.6%) Shareholding of Promoter and Promoter Group
Quant Mutual Fund 1064216.0 (2.33%) Public Shareholding
Atul Limited 958927.0 (2.1%) Public Shareholding
Parke, Davis & Company Llc 955733.0 (2.09%) Shareholding of Promoter and Promoter Group
John Wyeth & Brother Ltd 882000.0 (1.93%) Shareholding of Promoter and Promoter Group
Pharmacia Corporation 783941.0 (1.71%) Shareholding of Promoter and Promoter Group
Icici Prudential Mutual Fund 516658.0 (1.13%) Public Shareholding
Sbi Mutual Fund 516130.0 (1.13%) Public Shareholding

News

Left Arrow
Right Arrow

PFIZER LTD corporate actions

  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
11 Aug 2023 35.0 Final 11 Aug 2023 Equity shares
11 Aug 2023 5.0 Special 11 Aug 2023 Equity shares
19 Sep 2022 30.0 Special 20 Feb 2022 Equity shares
18 Aug 2022 35.0 Final 19 Aug 2022 Equity shares
11 Aug 2021 30.0 Final 13 Aug 2021 Equity shares
11 Aug 2021 5.0 Special 13 Aug 2021 Equity shares
27 Aug 2020 10.0 Final 29 Aug 2020 Equity shares
06 May 2020 320.0 Special 08 May 2020 Equity shares
01 Aug 2019 22.5 Final 03 Aug 2019 Equity shares
29 Aug 2018 20.0 Final 31 Aug 2018 Equity shares
22 Aug 2017 15.0 Final 24 Aug 2017 Equity shares
22 Aug 2017 5.0 Special 24 Aug 2017 Equity shares
27 Jun 2016 15.0 Final 29 Jun 2016 Equity shares
03 Jul 2015 12.5 Final 07 Jul 2015 Equity shares
05 Dec 2013 360.0 Interim 06 Dec 2013 Equity shares
28 Aug 2013 12.5 Final 30 Aug 2013 Equity shares
28 Aug 2013 20.0 Special 30 Aug 2013 Equity shares
24 Jul 2012 12.5 Final 26 Jul 2012 Equity shares
08 Jul 2011 4.0 Final 12 Jul 2011 Equity shares
20 Jan 2011 12.5 Interim 21 Jan 2011 Equity shares
15 Apr 2010 12.5 Final 17 Apr 2010 Equity shares
31 Mar 2009 12.5 Final 06 Apr 2009 Equity shares
03 Apr 2008 12.5 Interim 07 Apr 2008 Equity shares
03 Apr 2008 15.0 Special 07 Apr 2008 Equity shares
09 Mar 2007 22.5 Final 13 Mar 2007 Equity shares
10 Apr 2006 0.0 Final 13 Apr 2006 Equity shares
Ex-Date Ex-Bonus Ratio
28 Jun 2000 12 Jun 2000 1:1
Ex-Date Old FV NEW FV Record Date
[-] [-] [-] [-]
  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
11 Aug 2023 35.0 Final 11 Aug 2023 Equity shares
11 Aug 2023 5.0 Special 11 Aug 2023 Equity shares
19 Sep 2022 30.0 Special 20 Feb 2022 Equity shares
18 Aug 2022 35.0 Final 19 Aug 2022 Equity shares
11 Aug 2021 30.0 Final 13 Aug 2021 Equity shares
11 Aug 2021 5.0 Special 13 Aug 2021 Equity shares
27 Aug 2020 10.0 Final 29 Aug 2020 Equity shares
06 May 2020 320.0 Special 08 May 2020 Equity shares
01 Aug 2019 22.5 Final 03 Aug 2019 Equity shares
29 Aug 2018 20.0 Final 31 Aug 2018 Equity shares
22 Aug 2017 15.0 Final 24 Aug 2017 Equity shares
22 Aug 2017 5.0 Special 24 Aug 2017 Equity shares
27 Jun 2016 15.0 Final 29 Jun 2016 Equity shares
03 Jul 2015 12.5 Final 07 Jul 2015 Equity shares
05 Dec 2013 360.0 Interim 06 Dec 2013 Equity shares
28 Aug 2013 12.5 Final 30 Aug 2013 Equity shares
28 Aug 2013 20.0 Special 30 Aug 2013 Equity shares
24 Jul 2012 12.5 Final 26 Jul 2012 Equity shares
08 Jul 2011 4.0 Final 12 Jul 2011 Equity shares
20 Jan 2011 12.5 Interim 21 Jan 2011 Equity shares
15 Apr 2010 12.5 Final 17 Apr 2010 Equity shares
31 Mar 2009 12.5 Final 06 Apr 2009 Equity shares
03 Apr 2008 12.5 Interim 07 Apr 2008 Equity shares
03 Apr 2008 15.0 Special 07 Apr 2008 Equity shares
09 Mar 2007 22.5 Final 13 Mar 2007 Equity shares
10 Apr 2006 0.0 Final 13 Apr 2006 Equity shares
Ex-Date Ex-Bonus Ratio
28 Jun 2000 12 Jun 2000 1:1
Ex-Date Old FV NEW FV Record Date
[-] [-] [-] [-]

PFIZER LTD Share Price

Pfizer Limited is engaged in manufacturing, marketing, trading and export of pharmaceutical products. The Company offer a portfolio of 150 specialised medicines in 15 therapeutic areas across 4 business categories. It has its own manufacturing facility at Goa and Thane. It has the distinction of being the first pharmaceutical company in India to start clinical research. The Company sells products in nearly 185 countries having 43 manufacturing sites globally. Their 6 primary therapeutic areas includes, Internal Medicine, Oncology, Hospital, Vaccines, Inflammation & Immunology and Rare Diseases.

Pfizer Limited came to the Indian market on 21st November, 1950 through a company named Dumex Limited. The first production facility was set up at Darukhanna in Mumbai, where products like Protinex and Isonex (isoniazid - an anti -TB drug) were manufactured. Subsequently, this plant also produced Becosules and Corex.

In 1960, Pfizer established a large and modern plant at Thane, near Mumbai, which housed manufacturing, quality control and product research facilities. This plant won a number of national safety awards. In November of the year 1965, the Company had entered into a licence agreement with Pfizer Corporation continuing the royalty-free licence granted to it for the use of Pfizer processes, technical know-how, etc., relating to the manufacture of existing products in the pharmaceutical, veterinary and agricultural fields and giving the Company the right to obtain from Pfizer Corporation by Mutual agreement, technical know-how and other assistance relating to the manufacture of new items. A large research and development laboratory of the company at Thane was commissioned in the year 1969. As of 4th March of the year 1977, the company's status was changed as a public limited company. Piroxicam, a major anti-artharitic drug, was launched in India in the last quarter of the year 1989 under the brand name of DOLONEX. The former subsidiary Dumex Ltd was amalgamated with the company effect from 1st April of the year 1992 and also during the same year, the pharmaceuticals division introduced Dolmex' intramuscular injection. Development Operations (Dev Ops) India, formerly a part of the Clinical Research Division, was established in 1995. The operations started with the hiring of a statistician in 1995. Pfizer had acquired the animal healthcare operations of SmithKline Beecham in the year 1996.

The pace of work of Clinical Research Division was picked up in 1998 and this was followed by a substantial growth in terms of activities and resources, especially in data management. A dedicated Informatics group of the company for all technical and applications support has been available since 1997. The Company closed down its manufacturing plant at Ankleshwar with effect from 31st July of the year 1999. During the year 2000, PL made tie-up with Shantha Biotechnics for parallel marketing of its products. Express Pharma Biz Award came to company's hands in the year 2002 for overall performance. The operational merger between the company and Parke-Davis had been completed in the year 2002. A year after, in 2003, Pfizer had initiated the global implementation of 'Clinicopia Labelling and Clinicopia Supply Chain' a part of inferno's Clinical Trials management suite. In mid 2003, the Mumbai group was aligned under Dev Ops Europe to emphasize its focus on operations and facilitate more interactions and project engagements from all sites. In the year 2004, PL had entered into an agreement with Sanofi Synthelabo (India) Ltd for co-promotion of its product, Daxid. The Company's seven key brands (Corex, Becosules, Magnex, Dolonex, Gelusil, Minipress XL and Benadryl) had listed among the Top-100 Industry brands, in the year 2005.

Viagra was the first global brand launched in December of the year 2005, followed by Caduet (a combination of atorvastatin and amlodipine for treatment of patients with dyslipidemia and hypertension) and LYRICA (pregabalin, for treatment of neuropathic pain), both of which launched in the first quarter of 2006. The Company bagged Pharma Excellence Awards 2006 in 'Innovative Products of the Year' category for Exubera.

The global divesture of the OTC business to Johnson & Johnson in December 2006 and Pfizer, won a US Supreme Court appeal in April of the year 2007 that aimed to open the company's Lipitor cholesterol pill, the most widely prescribed drug in the world, to generic competition, also in end of the year 2007, the company had transferred its exclusive license to Johnson & Johnson for a total consideration of Rs 2,148.51 million. Pfizer had launched Champix, a non-nicotine smoking cessation prescription drug during February of the year 2008.

On 12 April 2009, Pfizer Investments Netherlands B.V., an indirect wholly-owned subsidiary of Pfizer Inc, announced that it will make a tender offer to acquire a 33.77% stake in Pfizer Limited from public shareholders at a price of Rs. 675 per share. Successful completion of this offer, assuming full acceptance, would raise the indirect stake of Pfizer Inc in Pfizer Limited to 75% from the current level of 41.23%. The offer will represent a total value of up to Rs 680 crore, or approximately USD 136 million.

The Board of Directors of Pfizer Ltd at its meeting held on 26 September 2009 approved the Scheme of Amalgamation of Duchem Laboratories Ltd (wholly owned subsidiary of Pfizer Ltd) and Pfizer Ltd. The Scheme is proposed to be effective 1 December 2008. The Transferor Company being the wholly owned subsidiary of Pfizer Ltd, no consideration shall be payable to the Transferor Company or its shareholders pursuant to the Amalgamation and the shares held by Pfizer Ltd and its nominees in the Transferor Company shall stand cancelled.

The Board of Directors of Pfizer Ltd at its meeting held on 6 February 2012 approved the sale of its animal health division by way of a slump sale to its wholly owned subsidiary (being incorporated) in consideration of approximately Rs 440 crore, subject to adjustment for working capital, to be paid by the wholly owned subsidiary (being incorporated) either in cash and/or by issue of shares (at par or premium) on such terms as may be agreed to by the Board of Directors. In July 2011, Pfizer Inc USA., the Ultimate Holding Company of Pfizer Ltd, announced that it was reviewing strategic alternatives for its global animal health business.

The Board of Directors of Pfizer Ltd at its meeting held on 8 November 2012 approved the sale of its animal health business to Pfizer Animal Health India Limited, a 100% indirect subsidiary of Pfizer Inc., USA for a consideration of Rs 471.60 crore.

Pfizer Ltd issued to all concerned a lock out notice on 1 August 2014 at its plant situated at Thane Belapur Road, K.U. Bazar P.O., Navi Mumbai (the Plant). This said notice for the proposed lock-out has been necessitated on account of several acts, as a result of which the Company is of the belief that it has become impossible for the management to continue with the operations of the Plant in a peaceful and productive manner. The above lock-out notice will have no impact on the business operations of the Company. The Company has in place a robust business continuity plan which will ensure that its medicines are available to the patients at all times.On 1 December 2014, Pfizer Limited announced the completion of the merger with Wyeth Limited. The Scheme of Amalgamation between Wyeth Limited and Pfizer Limited and their respective shareholders and creditors (Scheme) was sanctioned by the Bombay High Court vide its order dated 31 October 2014. As per the provisions of the Scheme, 7 (seven) equity shares of Rs. 10/- (Rupees Ten only) each fully paid up of Pfizer Limited, will be issued for every 10 (ten) equity shares of Rs.10/- (Rupees Ten only) each fully paid up held in Wyeth Limited. The merger places Pfizer Limited among the top 10 pharmaceutical companies in India by market share. Pfizer Inc., USA, through its subsidiaries holds the majority stake in both companies and will continue to remain the majority shareholder with an approximate 63.9% holding in Pfizer Limited, post-merger. Wyeth Ltd. is a market leader in vaccines and women's health. Wyeth has pioneered the introduction of several new therapies in India and was the first to launch hormone replacement therapy and conjugated pneumococcal vaccines for infants and adults.

On 15 July 2015, Pfizer Ltd has informed the stock exchanges that the company has intimated the concerned authorities that it intends to effect closure of its plant situated at Thane Belapur Road, K.U. Bazar P.O., Navi Mumbai ('the Plant') with effect from 16 September 2015. The decision to close the Plant is based on an assessment of its long term viability and its ability to achieve the needed production. There has practically been no production activity at this plant since 2013, and the closure will not impact the supply of any of the Company's medicines to patients.

On 24 September 2015, Pfizer Ltd informed the stock exchanges that the company has intimated the concerned authorities that it has withdrawn its notice dated 15 July 2015, whereby it had intended to effect closure of its plant situated at Thane Belapur Road, K.U. Bazar P. O., Navi Mumbai ('the Plant'), as the Company has entered into a Business Transfer Agreement to sell the Plant as a going concern to Vidhi Research & Development LLP. On 23 September 2015, Pfizer Ltd had informed the stock exchanges that it had entered into a Business Transfer Agreement (BTA) for the transfer of the Company's business at the Thane Plant as a going concern to Vidhi Research and Development LLP in accordance with the terms of the agreement for a lump sum consideration of Rs 178 crore.

On 14 March 2016, Pfizer Ltd. announced that it has discontinued the manufacture and sale of its drug 'Corex' with immediate effect in view of Government of India notification dated 10 March 2016 prohibiting the manufacture for sale, sale and distribution of fixed dose combination of Chlopheniramine Maleate + Codeine Syrup with immediate effect. The above prohibition is likely to have an adverse impact on the revenue and profitability of the company. The company is exploring all available options at its disposal. On the same day, the Delhi High Court granted an interim injunction suspending the operation of the said government notification banning the manufacture for sale, sale and distribution of fixed dose combination of Chlopheniramine Maleate + Codeine Syrup till the next date of hearing. Corex recorded sale of Rs 176 crore for the nine months period ended 31 December 2015.

On 13 May 2016, Pfizer Ltd. announced that it has signed an agreement for the sale of four products marketed by its Global Established Products business in India. The brands Neko Soap, Sloans, Ferradol and Waterburys Compound will be divested to Piramal Enterprises Limited, for a consideration of Rs 110 crore, subject to adjustments for inventory on closing. The closure of this transaction is subject to obtaining requisite regulatory approvals and fulfilment of certain conditions by the parties.

On 29 November 2016, Pfizer Ltd announced that has also decided to discontinue the manufacturing of the current Corex Cough Syrup formulation (Codeine Phosphate 10mg + Chlorpheniramine Maleate 4mg) as part of a comprehensive review of its respiratory offerings. The company will be launching a series of products as line extensions under the Corex brand name, starting with the first launch in December 2016 and subsequent launches over the next year. The company remains committed to providing a more comprehensive set of solutions in respiratory indications, while ensuring minimal impact towards patients resulting from the discontinuation of manufacturing of the current Corex Cough Syrup formulation. Corex Cough Syrup recorded a sale of Rs 244.48 crores for the financial year ended 31 March 2016.

On 18 January 2017, Pfizer Limited announced that it has entered into a Delegation of Authority (DoA) with AstraZeneca Pharma India Limited (AstraZeneca), pursuant to which AstraZeneca has granted certain authority to the company to conduct certain activities in India. The said DoA is a result of a global agreement whereby Pfizer Inc. through its affiliates acquired from AstraZeneca PLC (through its affiliates) the development and commercial rights of their late-stage small molecule anti-infectives business. By way of this DoA, the company has been granted the authority, inter alia, to carry out the activities of pricing and reimbursement negotiations, promotional, marketing, tendering, bidding, and distribution in relation the identified injectable antibiotic products. Pursuant to this, Meronem Injection which is currently marketed in India by AstraZeneca is expected to be transitioned to Pfizer Limited.

On 31 May 2017, Pfizer Limited (India) informed the stock exchanges that it has entered into an agreement with AstraZeneca AB, Sweden, to acquire the brand 'Neksium' in India for a value of Rs 75 crore. The transaction is subject to completion of requisite clearances. Neksium was launched in India in the year 2006 and has developed strong equity with prescribers as a leading, high quality product in the Anti-Peptic Ulcerant space. Neksium, with the active ingredient Esomeprazole belongs to a class of pharmaceutical preparations called Proton Pump Inhibitors' (PPI) which are used effectively for reducing the acid secretion in the stomach. It is widely prescribed for the treatment of conditions across the Acid Peptic Disorders (APD) spectrum. Neksium (esomeprazole) complements Pfizer Limited's existing product portfolio in the gastrointestinal (GI) therapeutic area.

Pfizer Inc., USA had announced on October 10, 2017 that it was considering a review of strategic alternatives for its Global Consumer Healthcare business. Further to this, in December 2018, Pfizer Inc. had announced the formation of a joint venture between Pfizer Inc. and GlaxoSmithKline Plc. to create a premier global consumer healthcare company with robust iconic brands. The Company had been informed by Pfizer Inc. that the brands Anne French and Anacin which are currently marketed by your Company will become a part of the portfolio of the Joint Venture company.

In 2019, Enbrel, the first Tumor Necrosis Factor (TNF) inhibitor was launched. It launched Zavicefta drug; in 2021, it launched Gastroesophageal Reflux Disease (GERD) Clinic.

The Company on September 30, 2021 entered into a business transfer agreement (BTA) with Mylan Pharmaceuticals Private Limited (Mylan), subsidiary of Viatris Inc to transfer certain primarily off-patent branded and generic established medicines business comprising of six brands which included Lyrica, Viagra, Celebrex, Amlogard, Daxid and Dilantin along with related business assets and liabilities of Upjohn Business as a going concern to Mylan for a consideration of Rs 180.48 Crore. As a result, the Company transferred Upjohn business along with related business assets and liabilities to Mylan effective August 1, 2022.

During the year 2022-23, the Company transferred its said Business Undertaking at Thane including the land, plant and machinery and all workmen employed to Vidhi Research & Development LLP effective February 24, 2023.

In FY 2023-24, Company launched Betrecep (Tofacitinib) in July, 2023 for the treatment of Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, and Ulcerative Colitis. Becosules Syrup and Gelusil Raft preparation was launched in February, 2024.

Parent organization MNC Associate
NSE symbol PFIZER
Founded 1950
stock

Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Share Price of Pfizer Ltd?

Answer Field

The share price of Pfizer Ltd for NSE is ₹ 4292.8 and for BSE is ₹ 4276.

What is the Market Cap of Pfizer Ltd?

Answer Field

The market cap of Pfizer Ltd for NSE is ₹ 1,96,38.60 Cr. and for BSE is ₹ 0.0 Cr. as of now.

What is the 52 Week High and Low of Pfizer Ltd?

Answer Field

The 52 Week High and Low of Pfizer Ltd for NSE is ₹ 6451.15 and ₹ 3701.00 and for BSE is ₹ 6452.85 and ₹ 3742.90.

How to Buy Pfizer Ltd share?

Answer Field

You can trade in Pfizer Ltd shares with Bajaj Broking by opening a Demat Account.

What is 1 year return for Pfizer Ltd?

Answer Field

The 1 year returns on the stock has been 0.83%.

What is the Current Share Price of Pfizer Ltd?

Answer Field

Pfizer Ltd share price is for NSE ₹ 4292.8 & for BSE ₹ 4276 as on Apr 30 2025 03:30 PM.

What is the Market Cap of Pfizer Ltd Share?

Answer Field

The market cap of Pfizer Ltd for NSE ₹ 1,96,38.60 & for BSE ₹ 0.0 as on Apr 30 2025 03:30 PM.

What is the P/E Ratio of Pfizer Ltd Share?

Answer Field

As on Apr 30 2025 03:30 PM the price-to-earnings (PE) ratio for Pfizer Ltd share is 31.94.

What is the PB ratio of Pfizer Ltd Share?

Answer Field

As on Apr 30 2025 03:30 PM, the price-to-book (PB) ratio for Pfizer Ltd share is 819.90.

How to Buy Pfizer Ltd Share?

Answer Field

You can trade in Pfizer Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Pfizer Ltd Share on Bajaj Broking App?

Answer Field

To buy Pfizer Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Pfizer Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|